Impact of Introducing Infliximab Biosimilars on Total Infliximab Consumption and Originator Infliximab Prices in Eight Regions: An Interrupted Time-Series Analysis

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

Extent: Online-Ressource, 1 online resource.

Language: Englisch

Bibliographic citation: Impact of Introducing Infliximab Biosimilars on Total Infliximab Consumption and Originator Infliximab Prices in Eight Regions: An Interrupted Time-Series Analysis ; volume:37 ; number:3 ; day:23 ; month:3 ; year:2023 ; pages:409-420 ; date:5.2023
BioDrugs ; 37, Heft 3 (23.3.2023), 409-420, 5.2023

Classification: Wirtschaft

Creator: Peng, Kuan
Blais, Joseph E.
Pratt, Nicole L.
Guo, Jeff Jianfei
Hillen, Jodie B.
Stanford, Tyman
Ward, Michael
Lai, Edward Chia-Cheng
Shin, Ju-Young
Tong, Xinning
Fan, Min
Cheng, Franco W. T.
Wu, Jing
Yeung, Winnie W. Y.
Lau, Chak-Sing
Leung, Wai Keung
Wong, Ian C. K.
Li, Xue

Contributor: SpringerLink (Online service)

DOI: 10.1007/s40259-023-00589-3

URN: urn:nbn:de:101:1-2023090910320583233281

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 10:51 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Peng, Kuan
Blais, Joseph E.
Pratt, Nicole L.
Guo, Jeff Jianfei
Hillen, Jodie B.
Stanford, Tyman
Ward, Michael
Lai, Edward Chia-Cheng
Shin, Ju-Young
Tong, Xinning
Fan, Min
Cheng, Franco W. T.
Wu, Jing
Yeung, Winnie W. Y.
Lau, Chak-Sing
Leung, Wai Keung
Wong, Ian C. K.
Li, Xue
SpringerLink (Online service)

Other Objects (12)

Antikörper gegen Remicade-Infliximab reagieren auch bei Biosimilars

Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases

Batch-to-Batch Consistency of SB4 and SB2, Etanercept and Infliximab Biosimilars

Subcutaneous infliximab in Crohn’s disease patients with previous immunogenic failure of intravenous infliximab

PF-06438179/GP1111: An Infliximab Biosimilar

Policy Options for Infliximab Biosimilars in Inflammatory Bowel Disease Given Emerging Evidence for Switching

Infliximab-induced hot kidneys on bone scintigraphy

Low infliximab serum trough levels and anti-infliximab antibodies are prevalent in rheumatoid arthritis patients treated with infliximab in daily clinical practice: results of an observational cohort study

Bestimmung von Infliximab und Anti-Infliximab-Antikörpern im Rahmen des Therapeutischen Drug- und Immunogenitäts-Monitoring bei chronisch entzündlichen Darmerkrankungen

Exposure to Infliximab During Pregnancy: Post-Marketing Experience

Correction to: PF-06438179/GP1111: An Infliximab Biosimilar

Hodgkin's Lymphoma in Crohn's Disease Treated with Infliximab

Antikörper gegen Remicade-Infliximab reagieren auch bei Biosimilars

Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases

Batch-to-Batch Consistency of SB4 and SB2, Etanercept and Infliximab Biosimilars

Subcutaneous infliximab in Crohn’s disease patients with previous immunogenic failure of intravenous infliximab

PF-06438179/GP1111: An Infliximab Biosimilar

Policy Options for Infliximab Biosimilars in Inflammatory Bowel Disease Given Emerging Evidence for Switching

Infliximab-induced hot kidneys on bone scintigraphy

Low infliximab serum trough levels and anti-infliximab antibodies are prevalent in rheumatoid arthritis patients treated with infliximab in daily clinical practice: results of an observational cohort study

Bestimmung von Infliximab und Anti-Infliximab-Antikörpern im Rahmen des Therapeutischen Drug- und Immunogenitäts-Monitoring bei chronisch entzündlichen Darmerkrankungen

Exposure to Infliximab During Pregnancy: Post-Marketing Experience

Correction to: PF-06438179/GP1111: An Infliximab Biosimilar

Hodgkin's Lymphoma in Crohn's Disease Treated with Infliximab

Antikörper gegen Remicade-Infliximab reagieren auch bei Biosimilars

Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases

Batch-to-Batch Consistency of SB4 and SB2, Etanercept and Infliximab Biosimilars

Subcutaneous infliximab in Crohn’s disease patients with previous immunogenic failure of intravenous infliximab

PF-06438179/GP1111: An Infliximab Biosimilar

Policy Options for Infliximab Biosimilars in Inflammatory Bowel Disease Given Emerging Evidence for Switching

Infliximab-induced hot kidneys on bone scintigraphy

Low infliximab serum trough levels and anti-infliximab antibodies are prevalent in rheumatoid arthritis patients treated with infliximab in daily clinical practice: results of an observational cohort study

Bestimmung von Infliximab und Anti-Infliximab-Antikörpern im Rahmen des Therapeutischen Drug- und Immunogenitäts-Monitoring bei chronisch entzündlichen Darmerkrankungen

Exposure to Infliximab During Pregnancy: Post-Marketing Experience

Correction to: PF-06438179/GP1111: An Infliximab Biosimilar

Hodgkin's Lymphoma in Crohn's Disease Treated with Infliximab

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Impact of Introducing Infliximab Biosimilars on Total Infliximab Consumption and Originator Infliximab Prices in Eight Regions: An Interrupted Time-Series Analysis

Object Details

References and Relationships

Classification and Topics

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Antikörper gegen Remicade-Infliximab reagieren auch bei Biosimilars

Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases

Batch-to-Batch Consistency of SB4 and SB2, Etanercept and Infliximab Biosimilars

Subcutaneous infliximab in Crohn’s disease patients with previous immunogenic failure of intravenous infliximab

PF-06438179/GP1111: An Infliximab Biosimilar

Policy Options for Infliximab Biosimilars in Inflammatory Bowel Disease Given Emerging Evidence for Switching

Infliximab-induced hot kidneys on bone scintigraphy

Low infliximab serum trough levels and anti-infliximab antibodies are prevalent in rheumatoid arthritis patients treated with infliximab in daily clinical practice: results of an observational cohort study

Bestimmung von Infliximab und Anti-Infliximab-Antikörpern im Rahmen des Therapeutischen Drug- und Immunogenitäts-Monitoring bei chronisch entzündlichen Darmerkrankungen

Exposure to Infliximab During Pregnancy: Post-Marketing Experience

Correction to: PF-06438179/GP1111: An Infliximab Biosimilar

Hodgkin's Lymphoma in Crohn's Disease Treated with Infliximab

Antikörper gegen Remicade-Infliximab reagieren auch bei Biosimilars

Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases

Batch-to-Batch Consistency of SB4 and SB2, Etanercept and Infliximab Biosimilars

Subcutaneous infliximab in Crohn’s disease patients with previous immunogenic failure of intravenous infliximab

PF-06438179/GP1111: An Infliximab Biosimilar

Policy Options for Infliximab Biosimilars in Inflammatory Bowel Disease Given Emerging Evidence for Switching

Infliximab-induced hot kidneys on bone scintigraphy

Low infliximab serum trough levels and anti-infliximab antibodies are prevalent in rheumatoid arthritis patients treated with infliximab in daily clinical practice: results of an observational cohort study

Bestimmung von Infliximab und Anti-Infliximab-Antikörpern im Rahmen des Therapeutischen Drug- und Immunogenitäts-Monitoring bei chronisch entzündlichen Darmerkrankungen

Exposure to Infliximab During Pregnancy: Post-Marketing Experience

Correction to: PF-06438179/GP1111: An Infliximab Biosimilar

Hodgkin's Lymphoma in Crohn's Disease Treated with Infliximab

Antikörper gegen Remicade-Infliximab reagieren auch bei Biosimilars

Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases

Batch-to-Batch Consistency of SB4 and SB2, Etanercept and Infliximab Biosimilars

Subcutaneous infliximab in Crohn’s disease patients with previous immunogenic failure of intravenous infliximab

PF-06438179/GP1111: An Infliximab Biosimilar

Policy Options for Infliximab Biosimilars in Inflammatory Bowel Disease Given Emerging Evidence for Switching

Infliximab-induced hot kidneys on bone scintigraphy

Low infliximab serum trough levels and anti-infliximab antibodies are prevalent in rheumatoid arthritis patients treated with infliximab in daily clinical practice: results of an observational cohort study

Bestimmung von Infliximab und Anti-Infliximab-Antikörpern im Rahmen des Therapeutischen Drug- und Immunogenitäts-Monitoring bei chronisch entzündlichen Darmerkrankungen

Exposure to Infliximab During Pregnancy: Post-Marketing Experience

Correction to: PF-06438179/GP1111: An Infliximab Biosimilar

Hodgkin's Lymphoma in Crohn's Disease Treated with Infliximab

Related objects

Reset password